Abstract
SummarySquamous cell carcinoma of the head and neck (HNSCC) is the sixth most common cancer and accounts for 890.000 cases 450.000 deaths worldwide annually. HNSCC is a heterogeneous disease affecting mainly elderly patients, who frequently suffer from significant comorbidities. Due to the aggressive tumor biology and high recurrence rates after curative treatment, it is essential to follow the evidence-based treatment recommendations outlined in the international guidelines, although it has to be emphasized that relevant data gaps and controversies exist such as the role of induction chemotherapy, de-intensification strategies or the role of immunotherapy in the locally advanced and recurrent/metastatic setting. These topics will be addressed in this article. Most importantly, interdisciplinary management of HNSCC patients is key for the optimal management at all disease stages.
Funder
Medical University of Vienna
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6(1):92.
2. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Alcohol consumption and ethyl carbamate. IARC Monogr Eval Carcinog Risks Hum. 2010;96:3–1383.
3. Tornesello ML, Perri F, Buonaguro L, et al. HPV-related oropharyngeal cancers: from pathogenesis to new therapeutic approaches. Cancer Lett. 2014;351(2):198–205.
4. Adelstein DJ, Ismaila N, Ku JA, et al. Role of treatment deintensification in the management of p16+ oropharyngeal cancer: aSCO provisional clinical opinion. J Clin Oncol. 2019;37(18):1578–89.
5. Koyfman SA, Ismaila N, Crook D, et al. Management of the neck in squamous cell carcinoma of the oral cavity and oropharynx: aSCO clinical practice guideline. J Clin Oncol. 2019;37(20):1753–74.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献